Projektbeschreibung
Innovationen zum Verständnis und zur Prävention von Adipositas bei Kindern
Adipositas im späten Jugendalter kann lang anhaltende schädliche Auswirkungen haben und zu schwerer Adipositas, Diabetes, Herz-Kreislauf-Erkrankungen, vorzeitigem Tod und Behinderungen führen. Die Behandlung von Adipositas in der Jugend kann jedoch positive Ergebnisse bringen. Angesichts der steigenden Adipositasraten bei Kindern in Europa ist es von entscheidender Bedeutung, wirksamen Präventions- und Behandlungsstrategien Priorität einzuräumen. Durch das EU-finanzierte Projekt OBELISK sollen die Ursachen der Adipositas aufgeklärt und eine Präzisionsmedizin für betroffene Kinder bereitgestellt werden. Die Forschungsgruppe wird Neuerungen beim Verständnis der molekularen Mechanismen vorstellen, die dem Zusammenspiel der ursächlichen Faktoren zugrunde liegen, die den Übergang zu Adipositas im Kindesalter entweder ermöglichen oder verhindern. Sie wird zudem Instrumente zur frühzeitigen Vorhersage entwickeln und mit Familien, wissenschaftlichen und medizinischen Gemeinschaften, Schulen, Gemeinden und der Industrie zusammenarbeiten.
Ziel
Obesity rates in late teens have increased in Europe from 6% in 1980 to 32%, with long-lasting effects on the prevalence of severe obesity, diabetes and cardiovascular disease, premature death and disability. Efficiently fighting adult obesity is difficult but prevention and treatment of obesity have proven to work better at young ages. OBELISK goal is to cut the roots of the pandemic of obesity in Europe targeting children first. OBELISK is focused on elucidating, Predicting, Preventing obesity and bringing Precision medicine for children with obesity. OBELISK medicine is also Participative (4P), leveraging the potential of social innovation through engagement with families, scientific and medical communities, daycare, schools, municipalities, industries to achieve success.
OBELISK objectives are: 1/ to bring breakthroughs in the molecular mechanisms by which causative factors interact to drive (or prevent) the transition from normal weight to obesity during childhood and to develop and exploit for prevention and treatment early predictive proprietary tools; 2/ to identify at least 3 novel childhood obesity genes with the prospect of identifying additional drug targets; 3/ to demonstrate the utility of targeted approaches to prevent childhood obesity; 4/ to bring breakthroughs in childhood obesity treatment including a real-life clinical study of a promising existing drug (GLP1R agonist) to reverse obesity in people with mutations predisposing to early severe obesity; 5/ to exploit the project results and disseminate best practices to prevent and treat childhood obesity, implementing education programs and translating OBELISK clinical results into guidelines and proposals for policy makers to change obesity care; 6/ to facilitate networking and exchanges with other actions and projects in order to optimize knowledge and joint activities.
OBELISK targeted approach should contribute to decrease by 35% the number of children with obesity becoming adults with obesity.
Wissenschaftliches Gebiet
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health sciencesclinical medicineendocrinologydiabetes
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health scienceshealth sciencespersonalized medicine
- medical and health scienceshealth sciencesnutritionobesity
Schlüsselbegriffe
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
HORIZON-HLTH-2022-STAYHLTH-01-two-stage
Andere Projekte für diesen Aufruf anzeigenFinanzierungsplan
HORIZON-RIA - HORIZON Research and Innovation ActionsKoordinator
75654 Paris
Frankreich